机构：[1]National Clinical Research Centre for Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China[2]BGI-Shenzhen, Shenzhen 518083, China[3]Dalian Institute of Chemical Physics, Chinese Academy of Science, Dalian, Liaoning Province, China[4]Ren JiHospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[5]The First Affiliated hospital of Wenzhou Medical University, ZhejiangProvince, China[6]Nanfang Hospital, Southern Medical University, Guangdong Province, China[7]Tong Ren Hospital, Shanghai Jiao Tong University School ofMedicine, Shanghai, China[8]Central Hospital of Minhang District, Shanghai, China[9]Qilu Hospital of Shandong University, Shandong Province, China[10]Fujian Provincial Hospital, Fujian Province, China[11]Shanghai Tenth People’s Hospital of Tong Ji University, Shanghai, China[12]Xuzhou Central Hospital,Jiangsu Province, China[13]Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[14]Chang Hai Hospital, Second MilitaryMedical University, Shanghai, China[15]Shanghai First People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[16]James D.Watson Institute of Genome Sciences, Hangzhou, Zhejiang Province, China[17]Johns Hopkins University School of Medicine, Baltimore, Maryland, USA[18]School of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong Province, China
Human gut microbiome is a promising target for managing type 2 diabetes (T2D). Measures altering gut microbiota like oral intake of probiotics or berberine (BBR), a bacteriostatic agent, merit metabolic homoeostasis. We hence conducted a randomized, double-blind, placebo-controlled trial with newly diagnosed T2D patients from 20 centres in China. Four-hundred-nine eligible participants were enroled, randomly assigned (1:1:1:1) and completed a 12-week treatment of either BBR-alone, probiotics+BBR, probiotics-alone, or placebo, after a one-week run-in of gentamycin pretreatment. The changes in glycated haemoglobin, as the primary outcome, in the probiotics+BBR (least-squares mean [95% CI], -1.04[-1.19, -0.89]%) and BBR-alone group (-0.99[-1.16, -0.83]%) were significantly greater than that in the placebo and probiotics-alone groups (-0.59[-0.75, -0.44]%, -0.53[-0.68, -0.37]%, P < 0.001). BBR treatment induced more gastrointestinal side effects. Further metagenomics and metabolomic studies found that the hypoglycaemic effect of BBR is mediated by the inhibition of DCA biotransformation by Ruminococcus bromii. Therefore, our study reports a human microbial related mechanism underlying the antidiabetic effect of BBR on T2D. (Clinicaltrial.gov Identifier: NCT02861261).
第一作者机构：[1]National Clinical Research Centre for Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Yifei,Gu Yanyun,Ren Huahui,et al.Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).[J].NATURE COMMUNICATIONS.2020,11(1):doi:10.1038/s41467-020-18414-8.
APA：
Zhang Yifei,Gu Yanyun,Ren Huahui,Wang Shujie,Zhong Huanzi...&Wang Weiqing.(2020).Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)..NATURE COMMUNICATIONS,11,(1)
MLA：
Zhang Yifei,et al."Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).".NATURE COMMUNICATIONS 11..1(2020)
综合性期刊